Table of contents
- Trial overview
- Who is being studied
- Trial designs and phases
- Main endpoints and outcome measures
- Treatment strategies being compared
- What patients should know about these studies
Trial overview
The trial data on “Haloperidol Decanoate” are part of clinical research in schizophrenia spectrum disorders, which include schizophrenia, schizoaffective disorder, schizophreniform disorder, and brief psychotic episode.[1][2][3]
These studies are designed to compare treatment strategies, not to describe the medicine itself. The main goals are to see how treatment affects symptoms, daily functioning, and thinking skills.[1][2][3]
Who is being studied
The studies include people with different forms of psychotic illness. One trial focuses on people who had a first-time treatment failure on first-line treatment, which means the first treatment did not work well enough.[1]
Another trial includes patients with schizophrenia spectrum disorder and uses a personalized medicine approach based on psychotic phenotype, which means the pattern or type of psychotic illness.[2]
A third trial studies people with a recent diagnosis of schizophrenia and schizophrenia spectrum disorders, with a focus on cognitive problems in early psychosis, which means the early phase of a psychotic illness.[3]
Trial designs and phases
All three trials are interventional, meaning researchers assign treatment strategies and then measure the results.[1][2][3]
Two of the studies are in Phase 3, and one is in Phase 4.[1][2][3]
The Phase 3 trials compare treatment strategies in larger groups, while the Phase 4 study looks at an already authorized drug in patients with recent schizophrenia.[1][2][3]
Main endpoints and outcome measures
The main endpoint in the first Phase 3 trial is the change in PANSS total score at six weeks. PANSS stands for Positive And Negative Syndrome Scale, a tool used to measure symptom severity in schizophrenia.[1]
The second Phase 3 trial measures functional remission at 24 months using the PSP score. PSP stands for Personal and Social Performance Scale and is used to measure how well a person functions in daily life and social roles.[2]
The Phase 4 study measures cognitive functioning using change in BACS App scores. BACS App is used to assess thinking skills such as memory and attention in schizophrenia.[3]
Treatment strategies being compared
In the first study, researchers compare early intensified pharmacological treatment with treatment as usual. The study also looks at results by treatment line and pays special attention to people who had a first treatment failure.[1]
In the second study, researchers compare dose reduction of antipsychotics with maintenance treatment. The study asks whether the effect depends on the person’s psychotic phenotype, especially cycloid psychosis versus non-cycloid psychosis.[2]
In the third study, researchers compare vortioxetine with treatment as usual for cognitive problems in early psychosis. The trial includes several authorized medicines in its intervention list, including Haloperidol Decanoate in the broader trial data provided.[3]
What patients should know about these studies
These trials are not simple drug-use studies. They are structured research projects that try to answer specific questions about which treatment approach works best for different patient groups.[1][2][3]
The studies use different time frames, from six weeks to 24 months, so they can measure both short-term symptom changes and longer-term functional outcomes.[1][2]
Because the trials focus on symptoms, functioning, and cognition, they may help researchers understand which treatment strategies are most useful for people with schizophrenia spectrum disorders.[1][2][3]
